Dr. Kate Cwynarski is a Haem-Oncologist specialising in Lymphoma and CLL at University College London Hospital, London, UK, and Honorary Associate Professor at UCL. She trained at King's College, Hammersmith Hospital and Royal Free Hospital, London UK and received her MRC-funded PhD in immunology at Imperial College, London, UK. Her sub-specialist interests include Central Nervous System (CNS) Lymphoma, T-cell Lymphomas, HIV-related, PTLD and high-grade B‑cell lymphomas. She is involved in CAR-T cell trials for refractory DLBCL and T-cell lymphomas. She leads the UK T cell Lymphoma Group and previously lead the UK CNSL Group and British Society for Haematology (BSH) Lymphoma Specialist Interest Group. She is involved in many clinical trials and has lead and co-authored BSH, EHA and BHIVA guidelines for the management of SCNSL, PCNSL, CNS prophylaxis, T cell lymphoma and primary medistinal B cell lymphoma.

Prof Cheah is a Haematologist at Sir Charles Gairdner Hospital in Perth, Australia. He graduated in Medicine from University of Western Australia and completed post-graduate training at Fremantle Hospital, Peter MacCallum Cancer Centre and MD Anderson Cancer Centre, returning to Perth in 2015. Prof Cheah is the lymphoma lead and fellowship program director at Sir Charles Gairdner Hospital, Director of Haematology at Linear Clinical Research, Founder and CEO of the charity Blood Cancer Research WA and current Chair of the Australasian Lymphoma Alliance. He has authored >140 publications and attracted >$15 million dollars in competitive grant funding. His research interests are novel therapeutic approaches in diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma and he has led multiple investigator-initiated trials in these areas. When not at work he will be found spending time with his two sons, on the saddle of a road bike or perfecting his home espresso brewing technique.

Dr Paul Yeh is a consultant haematologist and clinician-scientist with dual appointments at Monash Health and Monash University. He is the clinical lead for molecular haematology and myeloproliferative neoplasms at Monash Health. He supervises the malignant molecular haematology service at Monash Pathology which includes the use of Next Generation Sequencing (NGS) to profile haematologic malignancies. He is also the head of the Blood Cancer Biomarkers Laboratory in the School of Clinical Sciences at Monash Health. His laboratory’s research interest is in the use of novel molecular biomarkers to understand normal and malignant haematopoiesis.